These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 31954535

  • 1. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Matsuo K, Machida H, Grubbs BH, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM.
    Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
    [Abstract] [Full Text] [Related]

  • 2. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
    Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM.
    Gynecol Oncol; 2019 May; 153(2):230-237. PubMed ID: 30797590
    [Abstract] [Full Text] [Related]

  • 3. Evolving population-based statistics for rare epithelial ovarian cancers.
    Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, Wright JD.
    Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
    [Abstract] [Full Text] [Related]

  • 4. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
    Hannibal CG, Frederiksen K, Vang R, Kurman RJ, Kjaer SK.
    Int J Cancer; 2020 Aug 15; 147(4):990-995. PubMed ID: 31930502
    [Abstract] [Full Text] [Related]

  • 5. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
    Silberman JN, Bercow AS, Gockley AA, Eisenhauer EL, Sisodia R, Randall T, Del Carmen MG, Goodman A, Castro CM, Melamed A, Bregar AJ.
    Gynecol Oncol; 2023 Aug 15; 175():60-65. PubMed ID: 37327540
    [Abstract] [Full Text] [Related]

  • 6. Epidemiologic features of borderline ovarian tumors in California: a population-based study.
    Morris CR, Liu L, Rodriguez AO, Cress RD, Snipes K.
    Cancer Causes Control; 2013 Apr 15; 24(4):665-74. PubMed ID: 23314731
    [Abstract] [Full Text] [Related]

  • 7. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S.
    Cancer Treat Rev; 2015 Feb 15; 41(2):136-43. PubMed ID: 25573350
    [Abstract] [Full Text] [Related]

  • 8. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
    Wong KK, Bateman NW, Ng CW, Tsang YTM, Sun CS, Celestino J, Nguyen TV, Malpica A, Hillman RT, Zhang J, Futreal PA, Rojas C, Conrads KA, Hood BL, Dalgard CL, Wilkerson MD, Phippen NT, Conrads TP, Maxwell GL, Sood AK, Gershenson DM.
    J Transl Med; 2022 Dec 17; 20(1):606. PubMed ID: 36528667
    [Abstract] [Full Text] [Related]

  • 9. Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
    Petiot F, Descargues P, Devouassoux-Shisheboran M, You B, Rousset-Jablonski C, Raffin D, Hajri T, Gertych W, Glehen O, Philip CA, Lamblin G, Golfier F, Bolze PA.
    Eur J Obstet Gynecol Reprod Biol; 2024 Mar 17; 294():191-197. PubMed ID: 38295707
    [Abstract] [Full Text] [Related]

  • 10. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Matsuo K, Matsuzaki S, Nusbaum DJ, Maoz A, Oda K, Klar M, Roman LD, Sood AK.
    Gynecol Oncol; 2021 Jan 17; 160(1):32-39. PubMed ID: 33196436
    [Abstract] [Full Text] [Related]

  • 11. Low-grade Serous Tumors: Are We Making Progress?
    Pauly N, Ehmann S, Ricciardi E, Ataseven B, Bommert M, Heitz F, Prader S, Schneider S, du Bois A, Harter P, Baert T.
    Curr Oncol Rep; 2020 Jan 27; 22(1):8. PubMed ID: 31989304
    [Abstract] [Full Text] [Related]

  • 12. Low-grade serous ovarian carcinoma: A comprehensive literature review.
    Goulding EA, Simcock B, McLachlan J, van der Griend R, Sykes P.
    Aust N Z J Obstet Gynaecol; 2020 Feb 27; 60(1):27-33. PubMed ID: 31849044
    [Abstract] [Full Text] [Related]

  • 13. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.
    Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, Malpica A, Sun CC.
    J Clin Oncol; 2015 Aug 20; 33(24):2675-82. PubMed ID: 26195696
    [Abstract] [Full Text] [Related]

  • 14. Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001).
    Vatansever D, Taskiran C, Mutlu Meydanli M, Gungorduk K, Akbayir O, Yalcin I, Demirkiran F, Sozen H, Ozgul N, Celik H, Onan MA, Taskin S, Oge T, Simsek T, Abboud S, Yuksel IT, Ayhan A.
    J Surg Oncol; 2021 May 20; 123(8):1801-1810. PubMed ID: 33657253
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.